Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults
Public ClinicalTrials.gov record NCT07225413. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dose-Response Effects of Short-Term *Rhodiola Rosea* on Anaerobic Performance and Cognitive Function in Resistance-Trained Adults: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate whether 7 days of Rhodiola rosea (golden root) supplementation can improve resistance-exercise performance and cognitive function in resistance-trained men and women. Participants will complete four 7-day periods in a randomized, double-blind, crossover order: (1) no-capsule control, (2) placebo, (3) low-dose Rhodiola rosea, and (4) high-dose Rhodiola rosea. On day 7 of each period, they will report to the laboratory for performance testing that includes bench press and leg press 1-repetition maximum (1RM), a third set to failure at 60% 1RM, Tendo-derived mean and peak power, a 30-second Wingate test, and the paper-and-pencil Stroop Color-Word Test for executive function. Secondary outcomes include ratings of perceived exertion, readiness to perform (visual analog scale), and heart rate and blood pressure measured at rest and 1 minute after exercise. The central hypothesis is that short-term Rhodiola rosea, compared with control and placebo, will produce small but measurable improvements in strength, set-to-failure volume, and Stroop performance, with minimal changes in hemodynamics.
Study identification
- NCT ID
- NCT07225413
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Interventions
- Rhodiola rosea (low dose) Dietary Supplement
- Rhodiola rosea (high dose) Dietary Supplement
- Placebo capsules Dietary Supplement
Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Weeks to 40 Weeks
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2022
- Primary completion
- Oct 16, 2022
- Completion
- Dec 30, 2022
- Last update posted
- Nov 5, 2025
2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exercise Physiology and Nutrition Laboratory (EPNL) at Jacksonville State University | Jacksonville | Alabama | 36265 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07225413, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07225413 live on ClinicalTrials.gov.